Loading...
XTAE
XTLB
Market cap6mUSD
Jul 09, Last price  
2.00ILS
1D
0.00%
1Q
0.00%
Jan 2017
1,624.14%
IPO
-91.65%
Name

X T L Biopharmaceuticals Ltd

Chart & Performance

D1W1MN
XTAE:XTLB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.49%
Rev. gr., 5y
45.57%
Revenues
0k
-100.00%
454,000907,0005,940,000000938,0002,369,0000000000000451,0000
Net income
-7m
L+578.58%
-15,132,000-24,939,000-9,246,0002,587,000-1,257,000-1,207,000-1,390,000-2,476,000-2,527,000-4,311,000-2,545,000-781,0002,986,000-1,347,000-782,000435,000-1,348,000-1,782-1,027,000-6,969,000
CFO
-1m
L-36.65%
-12,587,000-21,457,000-10,578,000-2,488,000-735,000-1,801,000-1,506,000-2,499,000-2,470,000-1,861,000-1,732,000-1,125,000-816,000-908,000-850,000-1,049,000-901,000-707,000-1,618,000-1,025,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
URL
https://www.xtlbio.com/
IPO date
Sep 01, 2000
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT